Premium
Treatment of feline mammary tumours using chemotherapy, surgery and a COX‐2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002–2007) *
Author(s) -
Borrego J. F.,
Cartagena J. C.,
Engel J.
Publication year - 2009
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2009.00194.x
Subject(s) - meloxicam , medicine , chemotherapy , surgery , azotemia , cox 2 inhibitor , cats , urology , cyclooxygenase , biochemistry , chemistry , renal function , enzyme
The efficacy of a treatment combination of a COX‐2 inhibitor (meloxicam), chemotherapy and surgery in 23 cats with histologically confirmed mammary gland adenocarcinoma was evaluated. All of the cases underwent an aggressive surgery with concurrent doxorubicin‐based chemotherapy. Meloxicam was given orally starting the day after surgery and was continued indefinitely. Serum renal parameters were measured every 3–5 months. Three cats developed azotemia, whereas in four other renal parameters increased but remained within normal limit. The Kaplan–Meier median survival time was 460 days. The Kaplan–Meier median disease free interval was 269 days. The survival times are similar to other studies, not supporting the use of this treatment combination. Prospective studies with a higher number of cases are warranted to investigate the utility of this multimodality protocol for the treatment of feline mammary tumours.